

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 31, 2016

Bellicum Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36783
(Commission
File Number)

20-1450200
(IRS Employer
Identification No.)

2130 W. Holcombe Blvd., Ste. 800
Houston, TX
(Address of principal executive offices)

77030
(Zip Code)

Registrant's telephone number, including area code: (832) 384-1100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01 Entry into a Material Definitive Agreement.

On October 31, 2016, Bellicum Pharmaceuticals, Inc. (the "Company") and Ospedale Pediatrico Bambino Gesù ("OPBG"), entered into a collaboration agreement (the "Agreement") pursuant to which the Company and OPBG agreed to collaborate on research projects and early stage clinical trials for the design and development of various T cell immunotherapies (the "Research").

As consideration for OPBG's performance of the Research and grant of certain licenses to the Company, the Company agreed to fund an aggregate of up to \$4.4 million in project costs payable to OPBG or certain third party service providers, as applicable, over the term of the Research, estimated to be four years. With respect to any inventions arising from the Research, OPBG agreed to grant the Company an exclusive license to any such inventions, the terms of which will be set forth in a separate agreement. In addition, OPBG granted the Company paid-up, worldwide co-exclusive licenses for non-commercial development of OPBG's CD19 and CAR.GD2 CAR-T technologies, as well as paid-up, worldwide exclusive licenses to commercialize its CD19 and CAR.GD2 CAR-T technologies, each to be governed by a separate agreement.

The initial term of the Agreement expires on June 30, 2017, unless the parties agree to an extension. Either party may terminate the Agreement upon written notice delivered 30 days in advance if the Research fails and such failure cannot be remedied within 60 days of such notice. The Company may terminate the Agreement at any time upon providing OPBG with written notice 60 days in advance.

The description of the Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement, including the exhibits thereto, a copy of which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

On November 1, 2016, the Company issued a press release announcing the Agreement. A copy of this press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits**

Exhibit No.	Description
99.1	Press Release dated November 1, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bellicum Pharmaceuticals, Inc.

Dated: November 1, 2016

By: /s/ Ken Moseley

Ken Moseley

Senior Vice President and General Counsel

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated November 1, 2016.



Bellicum and Ospedale Pediatrico Bambino Gesù Announce Expanded Collaboration to Develop Novel CAR T and TCR Cell Therapies Engineered with CaspaCIDE

CaspaCIDE-enabled CD19 CAR T cell therapy to enter clinical development in 2017

Agreement broadened after clinical successes of BPX-501 with CaspaCIDE

Houston, TX and Rome, Italy - November 1, 2016 - Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) and Ospedale Pediatrico Bambino Gesù (OPBG), a leading European pediatric research center and hospital, today announced that they have entered into an expanded collaboration focused on preclinical and clinical development of CD19 and other CAR T and TCR therapeutics engineered with Bellicum's CaspaCIDE[®] molecular safety switch technology.

The two organizations agreed to jointly develop CARs and other cell therapies discovered by OPBG and engineered with Bellicum's CaspaCIDE safety switch, which is designed to reduce or eliminate cells that become toxic or are no longer needed. Under terms of this agreement, Bellicum agreed to provide financial support to the research collaboration in exchange for exclusive worldwide rights to commercialize certain cell therapies that are developed, while OPBG maintains rights for research purposes. OPBG will conduct research and clinical studies of CAR T and TCR therapeutics in pediatric patients, with initial CD19 CAR T and GD2 CAR T clinical trials in pediatric acute lymphoblastic leukemia and neuroblastoma patients, respectively, expected to start in 2017. In addition, OPBG agreed to manufacture European clinical trial supplies for the investigational programs, as well as Bellicum's PRAME-targeted TCR, BPX-701, in its GMP facility.

"The Ospedale Pediatrico Bambino Gesù is among the world's leading cell and gene therapy research centers and hospitals, and we are enthusiastic about working with them to develop controllable engineered T-cell therapies," commented Tom Farrell, President and CEO of Bellicum Pharmaceuticals. "This agreement builds on our highly successful clinical development collaboration with OPBG on BPX-501, our CaspaCIDE-enabled T-cell therapy in clinical development for patients undergoing haploidentical hematopoietic stem cell transplant. OPBG has developed several exciting and innovative new cell therapies, including a CD19 CAR T cell that we believe will be highly differentiated by virtue of our clinically validated CaspaCIDE safety switch."

"We have a highly productive and synergistic relationship with Bellicum, and look forward to building on our present research collaboration," commented Dr. Mariella Enoc, President of the Board of Directors of OPBG. "The combination of Bellicum's innovative safety switch

technology and our cell and gene therapy expertise, clinical study network and GMP vector and cell manufacturing capabilities, makes this an ideal partnership to rapidly advance controllable cell therapies that could benefit children and adults with life-threatening cancers throughout the world.”

About Ospedale Pediatrico Bambino Gesù

Bambino Gesù Children’s Hospital is a scientific institute for research and health care and is Italy’s main pediatric hospital providing advanced health care for children and performing basic, clinical and translational research activities. The hospital is widely recognized as a referral center for all pediatric specialties at national and international levels. The research laboratories are located in a brand-new and purpose-built research facility of 3,000 sqm. The Bambino Gesù Hospital has also built a new GMP Facility of 1,200 sqm equipped with 8 clean rooms for extensive cell manipulation, including gene therapy. The Department of Hematology/Oncology and Transfusion Medicine, chaired by Prof. Franco Locatelli, is the main Italian center for the care and research in the field of pediatric hematology and oncology and is credited as one of the most qualified worldwide in pediatric hematopoietic stem cell transplantation and adoptive immunotherapy for prevention and treatment of cancer relapse.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Forward-Looking Statement

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "designed," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to CAR Ts, to TCRs and to CaspaCIDE; the success of the collaboration with OPGB, the effectiveness of BPX-501, its possible range of application and potential curative effects and safety in the treatment of diseases including as compared to other treatment options and competitive therapies; the timing and success of our clinical trials, including clinical trials involving CD19 CAR T cells; the timing of regulatory filings for BPX-501; our research and development activities relating to BPX-501; and the potential applications of our product candidate BPX-501. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the

heading "Risk Factors" in Bellicum's filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2015 and our quarterly report on Form 10-Q for the quarter ended June 30, 2016. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investors:

Alan Musso, CFO
Bellicum Pharmaceuticals
832-384-1116

amusso@bellicum.com

Media:

Brad Miles
BMC Communications
646-513-3125

bmiles@bmccommunications.com